|Awarded On||November 16, 2016|
|Title||Developing Effective Immunotherapeutic Strategies for Advanced Uveal Melanoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Scott Woodman|
|Cancer Sites||Eye and Orbit|
Uveal melanoma (UM) is the most common eye tumor in adults. Although the tumor in the eye can be effectively treated, in half of cases, UM cells will have already traveled to other organs well before the initial diagnosis and later develop into lethal metastases. Metastatic UM patients have only a 10% one-year survival. No effective therapy exists. We aim to develop rational, more effective therapies for metastatic UM. Immune checkpoint blockade therapy (e.g., anti-CTLA-4, anti-PD-1) is revolutionizing cancer treatment. By taking off the “brakes” that immune cells naturally apply when confronting cancer cells, checkpoint blockade drugs enable the immune system to fight cancer cells. These a...